Summary#
This bill makes a very narrow change to the Public Health Service Act. It removes one subparagraph from section 351(k)(5) and renames the following subparagraph to take its place. The bill is described as aiming to “streamline the review of biosimilar biological products.”
- Main change: strike subparagraph (B) of 42 U.S.C. 262(k)(5) and redesignate subparagraph (C) as (B).
- Scope: the change is a single, textual edit to the law that governs FDA review of biosimilars (follow-on versions of licensed biological drugs).
- Policy goal (from the bill title): shorten or simplify the FDA review process for biosimilars.
- What is unclear: the bill text does not say what the removed subparagraph currently says or how removing it will change specific FDA rules, timelines, or legal procedures.
What it means for you#
- Biosimilar manufacturers: This bill targets the legal rules that govern biosimilar approval. It could affect how quickly or simply a company gets FDA clearance, but the bill itself does not spell out procedural details.
- Reference (innovator) biologic manufacturers: Companies that make the original biologic product may be affected if the deleted provision currently creates protections, information exchanges, or timing that benefit them. The bill does not specify any new protections.
- FDA and regulators: The agency would apply the statute as amended. The practical effect on review steps, timelines, or documentation requirements is not described in the bill.
- Patients and prescribers: The bill is meant to speed or streamline biosimilar reviews. If that happens, patients could gain faster access to biosimilars. The bill text does not guarantee faster patient access.
- Courts and legal disputes: Removing a statutory clause could change the legal basis for certain disputes about biosimilar approvals. The bill does not say how courts should interpret the change.
Expenses#
No publicly available information on costs is included in the bill text or the supplied material.
- There is no fiscal note, budget estimate, or cost analysis attached to this bill text.
- Possible effects (not stated in the bill): the change could reduce FDA workload for some procedures or shift legal and administrative work to other steps, but the bill does not provide estimates.
- Any costs for companies (compliance, litigation) or savings to the government are not identified in the supplied material.
Proponents' View#
- The bill appears intended to simplify or speed up FDA review of biosimilars, based on its title and the single-text change.
- A possible argument for the bill is that removing a statutory requirement could reduce procedural steps or delays in the approval process.
- Supporters may see this as helping biosimilar manufacturers bring products to market faster, which could increase competition.
Opponents' View#
- One concern is that deleting a statutory clause without explanation may create legal uncertainty about how FDA must handle biosimilar applications.
- The bill does not explain which protections, timelines, or information exchanges (if any) are being removed, so it is unclear whether the change could harm the ability of innovator companies to protect patents or otherwise challenge applications.
- The lack of a fiscal or implementation analysis means it is unclear whether the change will reduce costs, shift costs elsewhere, or increase litigation.
- It is unclear how courts will interpret the statutory gap created by removing the subparagraph or whether additional regulation or guidance will be needed to fill any gap.